Brief: NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation For Treating Narcolepsy
18/05/2021 13:24
May 18 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS ANNOUNCES NEW STUDY DATA CONFIRMING
MAZINDOL'S
UNIQUE OREXIN PATHWAY ACTIVATION FOR TREATING NARCOLEPSY
* NLS PHARMACEUTICS LTD. - POTENT OREXIN-2 RECEPTOR AGONIST
ACTIVITY OF MAZINDOL DEMONSTRATED IN KNOCK-OUT MOUSE MODEL
Source text for Eikon: ID:nPn137zB9a
Further company coverage: NLSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing